Up 7%: Insmed's Data Still Mixed

Insmed noted some good news in culture conversion, but is that really the big takeaway?

May 20, 2014 at 7:10PM

Insmed (NASDAQ:INSM) reported news regarding its treatment for resistant nontuberculous mycobacterial (NTM) lung infections, causing a 7% spike in the stock. Folks were excited about it, with Piper Jaffray reiterating an "Overweight" rating on the stock. Let's dive in to why.

After conducting a 12 week trial comparing Arikayce to placebo (plus standard of care in both cases), Insmed noted that 11 of 44 patients given Arikayce demonstrated negative mycobacterial cultures, compared to 3 of 45 patients on placebo. After achieving statistical significance for this secondary endpoint, Insmed allowed those on placebo to switch to Arikayce, leading to a total of 21 patients with negative cultures. The 21 patients was the news for today.

However, the big takeaway from the trial probably still is the primary endpoint of change in mycobacterial density -- and Arikayce whiffed, missing statistical significance by a fair margin (p-value of 0.148).

In the video below Motley Fool health care analysts David Williamson and Michael Douglass discuss the trial and the endpoints -- and what they think of the data.

Can Insmed beat this top stock?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers